Topical and biologic therapies for diabetic foot ulcers

Medical Clinics of North America

Volumn 97, Issue 5, 2013, Pages 883-898

  Richmond, Nicholas A ^a   Vivas, Alejandra C ^a   Kirsner, Robert S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic therapies; Diabetic foot ulcers; Topical antiseptics; Wound care

Indexed keywords

ANTIINFECTIVE AGENT; BECAPLERMIN; CADEXOMER IODINE; CELLULOSE; COLLAGEN; OXIDIZED REGENERATED CELLULOSE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; SILVER; THROMBOCYTE CONCENTRATE; TISSUE SCAFFOLD;

ACELLULAR DERMAL MATRIX; ANTIMICROBIAL ACTIVITY; BILAYERED HUMAN SKIN; BIOLOGICAL THERAPY; BOVINE BILAYER ACELLULAR MATRIX; COLLAGEN OXIDIZE REGENERATED CELLULOSE DRESSING; COST EFFECTIVENESS ANALYSIS; DERMAL SKIN SUBSTITUTE; DIABETIC FOOT; EXTRACELLULAR MATRIX; FIBROBLAST; FOAM DRESSING; GEL; HEALTH CARE QUALITY; HUMAN; HUMAN ACELLULAR DERMAL REGENERATIVE TISSUE MATRIX; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIS WOUND MATRIX; SKIN AUTOGRAFT; SKIN GRAFT; SMALL INTESTINE MUCOSA; SMALL INTESTINE SUBMUCOSA OASIS WOUND MATRIX; SUBMUCOSA; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING; TOPICAL TREATMENT; ULCER HEALING; WOUND CARE; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING;

BIOLOGIC THERAPIES; DIABETIC FOOT ULCERS; TOPICAL ANTISEPTICS; WOUND CARE;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; BANDAGES; COLLAGEN; COMBINED MODALITY THERAPY; DEBRIDEMENT; DIABETIC FOOT; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84883240776     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.03.014     Document Type: Review

References (68)

1. Margolis D.J., Kantor J., Berlin J.A. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999, 22:692-695.
2. Elek S.D. Experimental staphylococcal infections in the skin of man. Ann NY Acad Sci 1956, 65:85-90.
3. Krizek T.J., Pobson M.D., Kho E. Bacterial growth and skin graft survival. Surg Forum 1967, 18:518.
4. Lookingbill D.P., Miller S.M., Knowles R.C. Bacteriology of chronic leg ulcers. Arch Dermatol 1978, 114:1765-1768.
5. Bendy R.H., Nuccio P.A., Wolfe E., et al. Relationship of quantitative wound bacterial counts to healing of decubiti: effect of topical gentamicin. Antimicrobial Agents Chemother 1964, 10:147-155.
6. Trengrove N.J., Stacey M.C., McGechie D., et al. Qualitative bacteriology and leg ulcer healing. JWound Care 1996, 5:277-280.
7. Davies C.E., Hill K.E., Newcombe R.G., et al. Aprospective study of the microbiology of chronic venous leg ulcers to reevaluate the clinical predictive value of tissue biopsies and swabs. Wound Repair Regen 2007, 15:17-22.
8. Drosou A., Falabella A., Kirsner R.S. Antiseptics on wounds: an area of controversy. Wounds 2003, 15:149-166.
9. Balin A.K., Pratt L. Dilute povidone-iodine solutions inhibit human skin fibroblast growth. Dermatol Surg 2002, 28:210-214.
10. Damour O., Hua S.Z., Lasne F., et al. Cytotoxicity evaluation of antiseptics and antibiotics on cultured human fibroblasts and keratinocytes. Burns 1992, 18:479-485.
11. Zhou L.H., Nahm W.K., Badiavas E., et al. Slow release iodine preparation and wound healing: invitro effects consistent with lack of invivo toxicity in human chronic wounds. Br J Dermatol 2002, 146:365-374.
12. Apelqvist J., Ragnarson Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine and standard treatment. An economic analysis alongside a clinical trial. Acta Derm Venereol 1996, 76:231-235.
13. Mertz P.M., Oliveira-Gandia M.F., Davis S.C. The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus in acute wounds. Dermatol Surg 1999, 25:89-93.
14. Schwartz J.A., Lantis J.C., Gendics C., et al. Aprospective, non comparative, multicenter study to investigate the effect of cadexomer iodine on bioburden load and other wound characteristics in diabetic foot ulcers. Int Wound J 2013, 10(2):193-199.
15. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Int J Dermatol 1998, 37:390-396.
16. Floyer C., Wilkinson J.D. Treatment of venous leg ulcers with cadexomer iodine with particular reference to iodine sensitivity. Acta Chir Scand Suppl 1988, 544:60-61.
17. Harcup J.W., Saul P.A. Astudy of the effect of cadexomer iodine in the treatment of venous leg ulcers. Br J Clin Pract 1986, 40:360-364.
18. Moberg S., Hoffman L., Grennert M.L., et al. Arandomized trial of cadexomer iodine in decubitus ulcers. JAm Geriatr Soc 1983, 31:462-465.
19. Lansdown A.B. Silver 1: its antimicrobial properties and mechanism of action. JWound Care 2002, 11:125-130.
20. Wright J.B., Lam K., Burrell R.E. Wound management in an era of increasing bacterial antibiotic resistance: a role for topical silver treatment. Am J Infect Control 1998, 26:572-577.
21. Rayman G., Rayman A., Baker N.R., et al. Sustained silver-releasing dressing in the treatment of diabetic foot ulcers. Br J Nurs 2005, 14:109-114.
22. Jude E.B., Apelqvist J., Spraul M., et al. Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers. Diabet Med 2007, 24:280-288.
23. Raghow R. The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 1994, 8:823-831.
24. Veves A., Sheehan P., Pham H.T. Arandomized, controlled trial of Promogran (acollagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002, 137:822-827.
25. Kakagia D.D., Kazakos K.J., Xarchas K.C., et al. Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. JDiabet Complications 2007, 21:387-391.
26. Cullen B, Boyle C, Rennison T, etal. ORC/Collagen Matrix Containing Silver Controls Bacterial Bioburden while Retaining Dermal Cell Viability. Poster presented at EWMA Prague. May 2006.
27. Demling R.H., Niezgoda J.A., Haraway G.D., et al. Small intestinal submucosa wound matrix and full-thickness venous ulcers: preliminary results. Wounds 2004, 16:18-22.
28. Niezgoda J.A., Van Gils C.C., Frykberg R.G., et al. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care 2005, 18(5 Pt 1):258-266.
29. Stern R., McPherson M., Longaker M.T. Histologic study of artificial skin used in the treatment of full-thickness thermal injury. JBurn Care Rehabil 1990, 11(1):7-13.
30. Iorio M.L., Goldstein J., Adams M., et al. Functional limb salvage in the diabetic patient: the use of a collagen bilayer matrix and risk factors for amputation. Plast Reconstr Surg 2011, 127:260-267.
31. Clerici G., Caminiti M., Curci V., et al. The use of a dermal substitute to preserve maximal foot length in diabetic foot wounds with tendon and bone exposure following urgent surgical debridement for acute infection. Int Wound J 2010, 7:176-183.
32. Winters C.L., Brigido S.A., Liden B.A., et al. Amulticenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds. Adv Skin Wound Care 2008, 21:375-381.
33. Reyzelman A., Crews R.T., Moore J.C., et al. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J 2009, 6:196-208.
34. Caravaggi C., De Giglio R., Pritelli C., et al. HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers: a prospective, multicenter, controlled, randomized clinical trial. DiabetesCare 2003, 26:2853-2859.
35. Uccioli L., Giurato L., Ruotolo V., et al. Two-step autologous grafting using HYAFF scaffolds in treating difficult diabetic foot ulcers: results of a multicenter, randomized controlled clinical trial with long-term follow-up. Int J Low Extrem Wounds 2011, 10:80-85.
36. Steed D.L., Attinger C., Colaizzi T., et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen 2006, 14:680-692.
37. Margolis D.J., Kantor J., Santanna J., et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001, 24:483-488.
38. Kirsner R.S., Warriner R., Michela M., et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol 2010, 146:857-862.
39. Apligraf. 2010 Organogenesis. Available at: Accessed January 22, 2013. http://www.apligraf.com/professional/what_is_apligraf/index.html.
40. Veves A., Falanga V., Armstrong D.G., Apligraf Diabetic Foot Ulcer Study, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001, 24:290-295.
41. Edmonds M., European and Australian Apligraf Diabetic Foot Ulcer Study Group Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009, 8:11-18.
42. Hu S., Kirsner R.S., Falanga V., et al. Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Repair Regen 2006, 14:427-433.
43. Advanced biohealing, dermagraft 2007, Advanced BioHealing, Inc, Available at:, Accessed on January 22, 2013. http://www2.dermagraft.com/wp-content/uploads/2012/11/DG-1001-05_Dermagraft-Directions-for-Use.pdf.
44. Marston W.A., Hanft J., Norwood P., Dermagraft Diabetic Foot Ulcer Study Group, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003, 26:1701-1705.
45. Marston W.A. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices 2004, 1:21-31.
46. Nagai M.K., Embil J.M. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002, 2:211-218.
47. Papanas N., Maltezos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging 2008, 3:233-240.
48. Bhansali A., Venkatesh S., Dutta P., et al. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?. Diabetes Res Clin Pract 2009, 83:e13-e16.
49. Wieman T.J., Smiell J.M., Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998, 21:822-827.
50. Steed D.L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. JVasc Surg 1995, 21:71-78.
51. Margolis D.J., Bartus C., Hoffstad O., et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005, 13:531-536.
52. Poeschla E.M., Buschschacher G.L., Wong-Stall F. Etiology of cancer: viruses. Cancer: principles & practice of oncology 2001, 151. Lippincott Williams & Wilkins, Philadelphia. 6th edition. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
53. Herlyn M., Satyamoorthy K. Melanoma. Cancer: principles & practice of oncology 2001, 2010-2011. Lippincott Williams & Wilkins, Philadelphia. 6th edition. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
54. Louis D.N., Cavenee W.K. Neoplasms of the central nervous system. Cancer: principles & practice of oncology 2001, 2092. Lippincott Williams & Wilkins, Philadelphia. 6th edition. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
55. US prescribing information for Regranex [online]. Available at: Accessed on February 8, 2013. http://www.regranex.com/Prescribing%2520Info.php.
56. Papanas N., Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf 2010, 33:455-461.
57. Sandri G., Bonferoni M.C., Rossi S., et al. Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers. Int J Pharm 2012, 426:1-6.
58. Borzini P., Mazzucco L. Platelet gels and releasates. Curr Opin Hematol 2005, 12(6):473-479.
59. Lacci K.M., Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010, 83:1-9.
60. Yuan N.B., Long Y., Zhang X.X., et al. Study on the mechanism of autologous platelet-rich gel to treat the refractory diabetic dermal ulcers. Sichuan Da Xue Xue Bao Yi Xue Ban 2009, 40:292-294.
61. Cheong Leong D.K., Tan Benedict B.C., Loon Chew K.T. Autologous growth factors: a biological treatment in sports medicine. Proceedings of Singapore Healthcare 2010, 19:229-233.
62. Driver V.R., Hanft J., Fylling C.P., Autologel Diabetic Foot Ulcer Study Group, et al. Aprospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006, 52:68-70. 72, 74 passim.
63. Saad Setta H., Elshahat A., Elsherbiny K., et al. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. Int Wound J 2011, 8:307-312.
64. de Leon J.M., Driver V.R., Fylling C.P., et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Adv Skin Wound Care 2011, 24:357-368.
65. Dougherty E.J. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care 2008, 21:568-575.
66. Scimeca C.L., Bharara M., Fisher T.K., et al. Novel use of platelet-rich plasma to augment curative diabetic foot surgery. JDiabetes Sci Technol 2010, 4:1121-1126.
67. Kirsner R.S., Michela M., Stasik L., et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol 2010, 146(8):857-862.
68. Kantor J., Margolis D.J. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001, 27:347-351.